ORKA (Oruka Therapeutics) Revenue : $ Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Revenue?

Oruka Therapeutics's revenue for the six months ended in Mar. 2024 was $0.00 Mil. Oruka Therapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Mar. 2024. Oruka Therapeutics's Revenue per Share for the six months ended in Mar. 2024 was $0.00. Oruka Therapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Oruka Therapeutics Revenue Historical Data

The historical data trend for Oruka Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Revenue Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Revenue

Oruka Therapeutics Semi-Annual Data
	Mar24
Revenue	-

Competitive Comparison of Oruka Therapeutics's Revenue

For the Biotechnology subindustry, Oruka Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Revenue falls into.

Oruka Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Oruka Therapeutics (NAS:ORKA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Oruka Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.